Live Breaking News & Updates on Patent Trial And Appeal Board

Stay updated with breaking news from Patent trial and appeal board. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Fed Circuit rejects Cellect rehearing on double patenting

En banc petition concerning obviousness-type double-patenting rejected by the Court of Appeals | Decision on patent term adjustment has been closely followed by pharma companies, NYIPLA, and AIPLA. ....

Perry Shutterstock , Fed Circuit , Fus Court Of Appeals For The Federal Circuit , Patent Trial And Appeal Board , Us Patent And Trademark Office , Bviousness Type ,

Fusion Orthopedics latest to win patent infringement battle against Extremity

Fusion Orthopedics wins patent infringement case against Extremity Medical, Zimmer Biomet and Paragon 28. The USPTO s Patent Trial and Appeal Board ruled agains ....

Zimmer Biomet , Trademark Office Patent Trial , Trademark Office , Patent Trial , Appeal Board , Extremity Medical , Fusion Orthopedics , Fusion Orthopedic Intralock , Patent Trial And Appeal Board , Fusion Orthopedics , Zimmer Biomet , Paragon 28 , Ntralock Device , Atent 166 ,

US Patent Office won't review two Novo Nordisk patents for Wegovy, Ozempic

A U.S. Patent Office tribunal on Monday rejected challenges to two key patents owned by Novo Nordisk covering the active ingredient in its weight-loss and diabetes drugs Wegovy and Ozempic brought by a generic drugmaker that is hoping to sell generic versions of the blockbuster medications. The office's Patent Trial and Appeal Board denied the requests by Mylan Pharmaceuticals, which is owned by Viatris, to review the validity of the Wegovy and Ozempic patents. ....

West Virginia , United States , New York , Blake Brittain , David Bario , Novo Wegovy , Patrick Wingrove , Mylan Pharmaceuticals , A Us Patent Office , Novo Nordisk , Patent Trial , Appeal Board , Denmark Based Novo , Pennsylvania Based Viatris , Will Dunham , Mylan Pharmaceuticals , Us Patent Office , Diabetes Drugs , Active Ingredient , Patent Trial And Appeal Board , Generic Versions ,

US Patent Office won't review two Novo Nordisk patents for Wegovy, Ozempic

A U.S. Patent Office tribunal on Monday rejected challenges to two key patents owned by Novo Nordisk covering the active ingredient in its weight-loss and diabetes drugs Wegovy and Ozempic brought by a generic drugmaker that is hoping to sell generic versions of the blockbuster medications. The office's Patent Trial and Appeal Board denied the requests by Mylan Pharmaceuticals, which is owned by Viatris, to review the validity of the Wegovy and Ozempic patents. ....

New York , United States , West Virginia , Patrick Wingrove , David Bario , Novo Wegovy , Blake Brittain , A Us Patent Office , Mylan Pharmaceuticals , Novo Nordisk , Patent Trial , Appeal Board , Denmark Based Novo , Pennsylvania Based Viatris , Will Dunham , Mylan Pharmaceuticals , Us Patent Office , Diabetes Drugs , Active Ingredient , Patent Trial And Appeal Board , Generic Versions ,

Fish & Richardson Welcomes Nine Lateral Litigation Associates

MINNEAPOLIS, August 17, 2023 Fish & Richardson has welcomed nine lateral associates to the litigation practice group since the start of 2023. ....

United States , Liz Mccarthy , Georgea Otoole , Kevan Sumner , Brandon Pakkebier , Matthew Johnson , James Yang , Lucien Wang , Allison Elkman , Corrin Drakulich , Kara Grogan , Kimberlys Budd , Leonardp Stark , Massachusetts Supreme Judicial Court , Us District Court , United States Navy , Us International Trade Commission , Carderock Division , Naval Surface Warfare Center , Trademark Office , International Trade Commission , Us Court , Global Head , District Courts , Trade Commission , Patent Trial ,